Breast cancer and clinical utility of CA 15—3 and CEA
- 1 January 1995
- journal article
- research article
- Published by Informa UK Limited in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 55 (sup221), 87-92
- https://doi.org/10.3109/00365519509090570
Abstract
This manuscript summarizes the experiences with CA 15—3 and CEA obtained in 8 000 breast cancer patients. These markers were usually in normal range (CEA <6 μg/L, CA 15—3 <40 UL) before surgery and increased only before the development of distant metastases. 80% of all patients with metastases had elevated marker levels several months before or at the time of detection of metastases. Therefore CA 15—3 and CEA determinations should be used as an easy method for screening of metastases during follow-up of breast cancer patients.Keywords
This publication has 5 references indexed in Scilit:
- Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?British Journal of Cancer, 1994
- Routine follow-up of patients after primary therapy for early breast cancer: Changing concepts and challenges for the futureAnnals Of Oncology, 1993
- CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancerClinica Chimica Acta; International Journal of Clinical Chemistry, 1991
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- Follow up of patients with breast cancer.BMJ, 1985